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Hyperthermophilic archaea are of great interest in evolutionary microbiology, owing to their
ability to withstand high temperatures, and often extremes of pressure, pH and salinity.
Enzymes from these organisms1 may offer particular opportunities for asymmetric synthesis,
complementary to approaches with mesophilic enzymes,2 or those involving enzyme3 and
pathway4 reengineering. However, perhaps due to a bias that hyperthermophilic enzymes have
“narrow substrate specificities,”5 archaeal extremophiles remain a largely untapped resource
in asymmetric synthesis.6
Herein, we disclose a remarkably general Dynamic Reductive Kinetic Resolution (DYRKR)
entry into (S)-profens, including several important NSAIDs. The enzyme employed is alcohol
dehydrogenase (ADH)-10, one of 13 annotated ADHs in the hyperthermophile Sulfolobus
solfataricus. Protein phylogenetic analysis of this paralogous family indicates SsADH-10 is
most closely related to homologues in distant taxa (Fig. 1). The highest identity between
SsADH-10 and any other SsADHs is only 34%, suggesting that the SsADH family was
established prior to the emergence of other archaeal lineages. Though not described as such,
the SsADH-10 appears to be the only SsADH isozyme for which structural information is
available in the pdb.7
The requisite, 2-arylpropionaldehydes were readily assembled via Pd(0)-catalyzed arylation
of t-butyl propionate under Buchwald-Hartwig-type8 conditions, followed by reduction to the
aldehyde (LDBBA9 or LAH/DMP oxid-see SI). Optimal DYRKR conditions (Table 1-80°C,
pH 9) led to efficient throughput of rac-aldehyde to the (S)-2-arylpropionaldehyde, particularly
with m- and p-substitution. Notably, (S)-profenols corresponding to the NSAIDs naproxen
(3b, scaled to 1 gram @ 98% yield and 95% ee), ibuprofen (3d, IP), flurbiprofen (3h, FlP),
fenoprofen (3j, FP) and ketoprofen (3l, KP) were obtained in excellent yields (up to 96%) and
high enantioselectivity (up to 99 %).
Naproxen is FDA-approved as the active (S)-antipode. While most individuals can invert (R)-
ibuprofen to the (S)-antipode, the pathway is inefficient for KP10a and FlP.10b Moreover, the
recent observation that the profen-CoA thioester intermediates inhibit G6PDH,10c argues for
“chiral switching” to single (S)-antipodes.10d Entries into (S)-profens11,12 include asymmetric
dberkowitz1@ unl.edu; pblum1@unl.edu .
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hydrogenation (NP 98% ee, IP 97% ee),11g and hydroformylation (IP, 92% ee).11f DKR
processes include enantioselective crystallization (NP >99% ee),11b DYRKR with H2 as
reductant under Ru(II) catalysis (IP 92% ee),11d and lipase/Ru(II)-mediated-DKR of allylic
acetates, followed by Cu-mediated Grignard-arylation (FlP 97% ee;11c Knochel arylation:11e
IP 97% ee). The hydrovinylation/oxidation approach is impressive (IP, FP, FlP, NP >96% ee),
11a but access to KP requires late stage arylation. Thus, the broad side chain tolerance of
SsADH-10 makes the method presented here among the most generally (S)-selective.
To explore how these extended hydrophobic substrates bind to SsADH-10, docking was carried
out (Fig. 2) for the (S)-antipodes of flurbiprofenal, naproxenal, ketoprofenal and fenoprofenal.
A detailed discussion of the approach and results is provided in the SI. Briefly, W95 is seen as
enforcing (S)-selectivity, with ligands clustering into two distinct distal ring binding modes.
“Channel-gating”-L272 and L295 appear to form a hydrophobic pocket for naproxenal and
flurbiprofenal. For the more flexible ketoprofenal and fenoprofenal, edge-to-face interactions
with W117 and F49 are proposed.
From a practical viewpoint, we have also found that SsADH-10 may be engaged in a “thermal
recycling” approach that may be generalizable to other hyperthermophilic enzymes. Namely,
while 30 vol% cosolvent is often needed to dissolve hydrophobic DH substrates,13 we use a
higher T (80°C) @ just 5% EtOH (solvent and biorenewable reductant). Importantly, upon
completion of the reaction, cooling to rt allows the product to precipitate and be collected by
filtration (see TOC graphic and SI). Reclaimed SsADH may be recycled (5 cycles @ 94-96 %
ee). Given the growing interest in thermophilic enzymes in synthesis,1,14 and in engineering
thermostability into mesophilic enzymes,15 this “thermal switching” approach is likely to find
broad application, well beyond the domain of geothermal dehydrogenases.
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Figure 1.
Protein phylogeny of the SsADH proteins. A consensus neighbor joining distance tree is shown
of all SsADHs and homologues of highest sequence identity in related taxa. Distances are
indicated by the bar (lower left corner) and represent 10 substitutions per 100 residues. Percent
occurrence among 100 trees was greater than 50% for all nodes except those indicated with an
asterisk.
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Figure 2.
Structures of thermally relaxed (GROMACS 4.07) SsADH-10 (from 1R37) to which has been
docked (Autodock Vina - left to right-): (i) (S)-flurbiprofenal (ii) (S)-naproxenal (iii) (S)-
ketoprofenal and (iv) (S)-fenoprofenal (Zn ligation sphere: H68, C38, C154 and substrate
carbonyl)
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Table 1
SsADH10-Mediated DYRKR Entry into Profenols
Cpd
No.
DYRKR
Producta t(h)
Yield
(%)b
ee
(%)c
3a 18 57% 94%
3b 18 96% 98%
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Cpd
No.
DYRKR
Producta t(h)
Yield
(%)b
ee
(%)c
3c 18 90% 80%
3d 18 92% 99%
3e 18 74% 98%
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Cpd
No.
DYRKR
Producta t(h)
Yield
(%)b
ee
(%)c
2f (redn not obsd) 18 recvd SM NA
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Cpd
No.
DYRKR
Producta t(h)
Yield
(%)b
ee
(%)c
3g 18 99% 90%
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Cpd
No.
DYRKR
Producta t(h)
Yield
(%)b
ee
(%)c
3h 18 77% 97%
3i 24 55% 98%
3j 12 85% 95%
3k 18 95% 61%
3l 18 85% 95%
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a
DYRKR performed on a 1 mmol scale (1 mol% NADH; 5 vol% EtOH)
b
Isolated yields
c
ee’s by chiral LC or GC. Blue - profen drug precursor.
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